
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta http-equiv="X-UA-Compatible" content="ie=edge">
<title>BCM Breast Cancer Trials</title>
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Nunito:wght@300;400;500;600;700&display=swap" rel="stylesheet">
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/markmap-toolbar@0.17.0/dist/style.css">
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/katex@0.16.8/dist/katex.min.css">
<style>
:root {
  --bg-gradient-start: #f8fafc;
  --bg-gradient-end: #e2e8f0;
  --header-bg: rgba(255, 255, 255, 0.95);
  --text-primary: #1e293b;
  --text-secondary: #64748b;
  --accent: #3b82f6;
  --accent-hover: #2563eb;
  --border: #e2e8f0;
  --shadow: rgba(0, 0, 0, 0.1);
  --status-open: #10b981;
  --status-opening: #f59e0b;
  --status-closing: #f97316;
  --status-closed: #ef4444;
  --card-bg: rgba(255, 255, 255, 0.9);
  --node-text: #1e293b;
}

[data-theme="dark"] {
  --bg-gradient-start: #0f172a;
  --bg-gradient-end: #1e293b;
  --header-bg: rgba(15, 23, 42, 0.95);
  --text-primary: #f1f5f9;
  --text-secondary: #94a3b8;
  --accent: #60a5fa;
  --accent-hover: #3b82f6;
  --border: #334155;
  --shadow: rgba(0, 0, 0, 0.3);
  --card-bg: rgba(30, 41, 59, 0.9);
  --node-text: #f1f5f9;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

body {
  font-family: 'Nunito', Tahoma, Geneva, Verdana, sans-serif;
  background: linear-gradient(135deg, var(--bg-gradient-start) 0%, var(--bg-gradient-end) 100%);
  min-height: 100vh;
  color: var(--text-primary);
  transition: background 0.3s ease, color 0.3s ease;
}

/* Header */
.header {
  position: fixed;
  top: 0;
  left: 0;
  right: 0;
  height: 64px;
  background: var(--header-bg);
  backdrop-filter: blur(12px);
  border-bottom: 1px solid var(--border);
  display: flex;
  align-items: center;
  justify-content: space-between;
  padding: 0 24px;
  z-index: 1000;
  box-shadow: 0 1px 3px var(--shadow);
}

.header-left {
  display: flex;
  align-items: center;
  gap: 16px;
}

.logo {
  width: 40px;
  height: 40px;
  background: linear-gradient(135deg, #ec4899 0%, #8b5cf6 100%);
  border-radius: 10px;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: 700;
  color: white;
  font-size: 18px;
}

.title-section h1 {
  font-size: 18px;
  font-weight: 600;
  color: var(--text-primary);
}

.title-section .subtitle {
  font-size: 12px;
  color: var(--text-secondary);
}

.header-right {
  display: flex;
  align-items: center;
  gap: 12px;
}

/* Search */
.search-container {
  position: relative;
}

.search-input {
  width: 280px;
  padding: 10px 16px 10px 40px;
  border: 1px solid var(--border);
  border-radius: 10px;
  background: var(--card-bg);
  color: var(--text-primary);
  font-size: 14px;
  font-family: inherit;
  transition: all 0.2s ease;
}

.search-input:focus {
  outline: none;
  border-color: var(--accent);
  box-shadow: 0 0 0 3px rgba(59, 130, 246, 0.1);
}

.search-input::placeholder {
  color: var(--text-secondary);
}

.search-icon {
  position: absolute;
  left: 12px;
  top: 50%;
  transform: translateY(-50%);
  color: var(--text-secondary);
  pointer-events: none;
}

.search-results {
  position: absolute;
  top: calc(100% + 8px);
  left: 0;
  right: 0;
  background: var(--card-bg);
  backdrop-filter: blur(12px);
  border: 1px solid var(--border);
  border-radius: 12px;
  max-height: 320px;
  overflow-y: auto;
  display: none;
  box-shadow: 0 10px 40px var(--shadow);
}

.search-results.active {
  display: block;
}

.search-result-item {
  padding: 12px 16px;
  cursor: pointer;
  border-bottom: 1px solid var(--border);
  transition: background 0.15s ease;
}

.search-result-item:last-child {
  border-bottom: none;
}

.search-result-item:hover {
  background: var(--accent);
  color: white;
}

.search-result-item .trial-name {
  font-weight: 500;
  font-size: 14px;
}

.search-result-item .trial-path {
  font-size: 12px;
  opacity: 0.7;
  margin-top: 2px;
}

/* Theme Toggle */
.theme-toggle {
  width: 44px;
  height: 44px;
  border: 1px solid var(--border);
  border-radius: 10px;
  background: var(--card-bg);
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  justify-content: center;
  transition: all 0.2s ease;
}

.theme-toggle:hover {
  border-color: var(--accent);
  color: var(--accent);
}

/* Legend */
.legend {
  position: fixed;
  bottom: 24px;
  left: 24px;
  background: var(--card-bg);
  backdrop-filter: blur(12px);
  border: 1px solid var(--border);
  border-radius: 12px;
  padding: 16px;
  z-index: 100;
  box-shadow: 0 4px 20px var(--shadow);
  min-width: 180px;
}

.legend h3 {
  font-size: 12px;
  font-weight: 600;
  text-transform: uppercase;
  letter-spacing: 0.5px;
  color: var(--text-secondary);
  margin-bottom: 12px;
}

.legend-item {
  display: flex;
  align-items: center;
  gap: 10px;
  padding: 6px 0;
  font-size: 13px;
}

.legend-dot {
  width: 12px;
  height: 12px;
  border-radius: 50%;
  flex-shrink: 0;
}

.legend-dot.open { background: var(--status-open); }
.legend-dot.opening { background: var(--status-opening); }
.legend-dot.closing { background: var(--status-closing); }
.legend-dot.closed { background: var(--status-closed); }

.legend-text {
  color: var(--text-primary);
}

.legend-text span {
  color: var(--text-secondary);
  font-size: 11px;
}

/* Stats */
.stats {
  position: fixed;
  top: 80px;
  right: 24px;
  display: flex;
  gap: 12px;
  z-index: 100;
}

.stat-card {
  background: var(--card-bg);
  backdrop-filter: blur(12px);
  border: 1px solid var(--border);
  border-radius: 12px;
  padding: 12px 16px;
  text-align: center;
  min-width: 80px;
  box-shadow: 0 4px 12px var(--shadow);
}

.stat-number {
  font-size: 24px;
  font-weight: 700;
  color: var(--accent);
}

.stat-label {
  font-size: 11px;
  color: var(--text-secondary);
  text-transform: uppercase;
  letter-spacing: 0.5px;
  margin-top: 2px;
}

/* Mindmap */
#mindmap {
  display: block;
  width: 100vw;
  height: calc(100vh - 64px);
  margin-top: 64px;
}

/* Custom node styles */
#mindmap .markmap-node {
  transition: opacity 0.3s ease;
}

#mindmap .markmap-node.dimmed {
  opacity: 0.2;
}

#mindmap .markmap-node-circle {
  transition: r 0.2s ease, fill 0.2s ease;
}

#mindmap .markmap-node:hover .markmap-node-circle {
  r: 6;
}

/* SVG text styling - IMPORTANT for dark mode */
#mindmap .markmap-node text {
  font-family: 'Nunito', Tahoma, Geneva, Verdana, sans-serif !important;
  fill: var(--node-text) !important;
  transition: fill 0.3s ease;
}

/* Override for status colors - applied via JS */
#mindmap .markmap-node text.status-opening {
  fill: var(--status-opening) !important;
}

#mindmap .markmap-node text.status-closing {
  fill: var(--status-closing) !important;
}

#mindmap .markmap-node text.status-closed {
  fill: var(--status-closed) !important;
  opacity: 0.6;
}

/* Toolbar override */
.mm-toolbar {
  background: var(--card-bg) !important;
  backdrop-filter: blur(12px);
  border: 1px solid var(--border) !important;
  border-radius: 12px !important;
  box-shadow: 0 4px 20px var(--shadow) !important;
}

.mm-toolbar-brand {
  display: none !important;
}

/* Scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: transparent;
}

::-webkit-scrollbar-thumb {
  background: var(--border);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: var(--text-secondary);
}

/* Animations */
@keyframes fadeIn {
  from { opacity: 0; transform: translateY(-10px); }
  to { opacity: 1; transform: translateY(0); }
}

.header, .legend, .stats {
  animation: fadeIn 0.4s ease;
}

/* Mobile adjustments */
@media (max-width: 768px) {
  .search-input {
    width: 200px;
  }

  .stats {
    display: none;
  }

  .legend {
    bottom: auto;
    top: 80px;
    left: 12px;
    transform: scale(0.9);
    transform-origin: top left;
  }
}
</style>
</head>
<body>

<!-- Header -->
<header class="header">
  <div class="header-left">
    <div class="logo">BC</div>
    <div class="title-section">
      <h1>BCM Breast Cancer Trials</h1>
      <div class="subtitle">Last updated: February 20, 2026 at 05:18 PM</div>
    </div>
  </div>
  <div class="header-right">
    <div class="search-container">
      <svg class="search-icon" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
        <circle cx="11" cy="11" r="8"></circle>
        <path d="m21 21-4.35-4.35"></path>
      </svg>
      <input type="text" class="search-input" placeholder="Search trials..." id="searchInput">
      <div class="search-results" id="searchResults"></div>
    </div>
    <button class="theme-toggle" id="themeToggle" title="Toggle dark mode">
      <svg class="sun-icon" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
        <circle cx="12" cy="12" r="5"></circle>
        <path d="M12 1v2M12 21v2M4.22 4.22l1.42 1.42M18.36 18.36l1.42 1.42M1 12h2M21 12h2M4.22 19.78l1.42-1.42M18.36 5.64l1.42-1.42"></path>
      </svg>
    </button>
  </div>
</header>

<!-- Legend -->
<div class="legend">
  <h3>Trial Status</h3>
  <div class="legend-item">
    <div class="legend-dot open"></div>
    <div class="legend-text"><strong>Bold</strong> <span>= Open</span></div>
  </div>
  <div class="legend-item">
    <div class="legend-dot opening"></div>
    <div class="legend-text">[OPENING] <span>= Coming Soon</span></div>
  </div>
  <div class="legend-item">
    <div class="legend-dot closing"></div>
    <div class="legend-text">[CLOSING] <span>= Closing Soon</span></div>
  </div>
  <div class="legend-item">
    <div class="legend-dot closed"></div>
    <div class="legend-text">[CLOSED] <span>= Closed</span></div>
  </div>
</div>

<!-- Stats (pre-calculated) -->
<div class="stats">
  <div class="stat-card">
    <div class="stat-number">67</div>
    <div class="stat-label">Open</div>
  </div>
  <div class="stat-card">
    <div class="stat-number">78</div>
    <div class="stat-label">Total</div>
  </div>
</div>

<!-- Mindmap -->
<svg id="mindmap"></svg>

<script src="https://cdn.jsdelivr.net/npm/d3@7.8.5/dist/d3.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/markmap-view@0.17.0/dist/browser/index.js"></script>
<script src="https://cdn.jsdelivr.net/npm/markmap-toolbar@0.17.0/dist/index.js"></script>
<script>
// Theme toggle
const themeToggle = document.getElementById('themeToggle');
const prefersDark = window.matchMedia('(prefers-color-scheme: dark)').matches;
const savedTheme = localStorage.getItem('theme');

if (savedTheme === 'dark' || (!savedTheme && prefersDark)) {
  document.documentElement.setAttribute('data-theme', 'dark');
}

themeToggle.addEventListener('click', () => {
  const isDark = document.documentElement.getAttribute('data-theme') === 'dark';
  document.documentElement.setAttribute('data-theme', isDark ? 'light' : 'dark');
  localStorage.setItem('theme', isDark ? 'light' : 'dark');
  // Re-apply styles after theme change
  startStyleUpdater();
});

// Markmap initialization
const root = {"content":"BCM Breast Cancer Trials","children":[{"content":"CLOSED","children":[{"content":"Adjuvant","children":[{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"4,5\"><strong>MA39</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Newly Diagnosis of IDC w/ no metastisis<br>\nTreated with BCS or Mastectomy with no residual disease","children":[],"payload":{"lines":"6,8"}}],"payload":{"lines":"4,8"}}],"payload":{"lines":"3,8"}}],"payload":{"lines":"2,8"}}],"payload":{"lines":"1,8"}},{"content":"Peri-Surgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"11,12\"><strong>CHEST</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Undergoing Mastectomy + Reconstruction","children":[],"payload":{"lines":"13,14"}}],"payload":{"lines":"11,14"}}],"payload":{"lines":"10,14"}}],"payload":{"lines":"9,14"}}],"payload":{"lines":"8,14"}},{"content":"Presurgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"17,18\"><strong>ATUSA-iSONO</strong></p>","children":[{"content":"\n<p data-lines=\"19,20\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Women with a suspected breast lesion in one of both breasts</p>","children":[],"payload":{"lines":"19,22"}},{"content":"\n<p data-lines=\"22,23\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Disease T1c or larger</p>","children":[],"payload":{"lines":"22,23"}}],"payload":{"lines":"17,23"}}],"payload":{"lines":"16,23"}}],"payload":{"lines":"15,23"}}],"payload":{"lines":"14,23"}}],"payload":{"lines":"0,23"}},{"content":"MED ONC","children":[{"content":"Adjuvant","children":[{"content":"HER2","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"27,28\"><strong>FLAMINGO -01</strong></p>","children":[{"content":"\n<p data-lines=\"29,30\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Stage I/II with nonpCR OR stage III (pCR or not) to be enorlled &lt;90 days from completion of HP/TDM1</p>","children":[],"payload":{"lines":"29,32"}},{"content":"\n<p data-lines=\"32,33\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TWO cohorst depending on HLA-A-02</p>","children":[],"payload":{"lines":"32,33"}}],"payload":{"lines":"27,33"}},{"content":"\n<p data-lines=\"33,34\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"35,36\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"35,38"}},{"content":"\n<p data-lines=\"38,39\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"38,39"}}],"payload":{"lines":"33,39"}},{"content":"\n<p data-lines=\"39,40\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"41,42"}}],"payload":{"lines":"39,42"}},{"content":"\n<p data-lines=\"42,43\"><strong>ADEPT [CLOSED 03/2026]</strong></p>","children":[{"content":"\n<p data-lines=\"44,45\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ OR PR+ with HER2+ disease T1A/B/C. N1mi allowed.</p>","children":[],"payload":{"lines":"44,47"}},{"content":"\n<p data-lines=\"47,48\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No more than 8 weeks of ET</p>","children":[],"payload":{"lines":"47,48"}}],"payload":{"lines":"42,48"}}],"payload":{"lines":"26,48"}}],"payload":{"lines":"25,48"}},{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"50,51\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"52,53\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"52,55"}},{"content":"\n<p data-lines=\"55,56\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"55,56"}}],"payload":{"lines":"50,56"}},{"content":"\n<p data-lines=\"56,57\"><strong>OFSET (NRG BR009)</strong></p>","children":[{"content":"\n<p data-lines=\"58,59\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ (&gt;1%) HER2- with pT1-3 pN0-1.</p>","children":[],"payload":{"lines":"58,61"}},{"content":"\n<p data-lines=\"61,62\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> RS N1 &lt;26. RS N0 21-25. RS N0 16-20 WITH T minimum at 30mm (G1), 20mm (G2) or 10mm (G3)</p>","children":[],"payload":{"lines":"61,62"}}],"payload":{"lines":"56,62"}},{"content":"\n<p data-lines=\"62,63\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"64,65"}}],"payload":{"lines":"62,65"}},{"content":"\n<p data-lines=\"65,66\"><strong>ELEGANT</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ High Risk (Defined by trial) between year 2 and 5 of adjuvant ET +/- CDK4/6i or PARPi","children":[],"payload":{"lines":"67,68"}}],"payload":{"lines":"65,68"}}],"payload":{"lines":"49,68"}}],"payload":{"lines":"48,68"}},{"content":"TNBC","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"70,71\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"72,73\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"72,75"}},{"content":"\n<p data-lines=\"75,76\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"75,76"}}],"payload":{"lines":"70,76"}},{"content":"\n<p data-lines=\"76,77\">MK-2870 [OPENING 05/2026]</p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Have residual Disease post NACT","children":[],"payload":{"lines":"78,79"}}],"payload":{"lines":"76,79"}},{"content":"\n<p data-lines=\"79,80\"><strong>OptimICE-PCR</strong></p>","children":[{"content":"\n<p data-lines=\"81,82\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC (ER/PR &lt;10%)  T1cN1-2 or T2-4N0-2 with ypT0 OR ypTis</p>","children":[],"payload":{"lines":"81,84"}},{"content":"\n<p data-lines=\"84,85\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adju RT  and Pembro, followed by registration</p>","children":[],"payload":{"lines":"84,85"}}],"payload":{"lines":"79,85"}},{"content":"\n<p data-lines=\"85,86\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"87,88"}}],"payload":{"lines":"85,88"}}],"payload":{"lines":"69,88"}}],"payload":{"lines":"68,88"}}],"payload":{"lines":"24,88"}},{"content":"Metastatic","children":[{"content":"HER2","children":[{"content":"2","children":[{"content":"\n<p data-lines=\"91,92\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"93,94\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"93,96"}},{"content":"\n<p data-lines=\"96,97\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"96,97"}}],"payload":{"lines":"91,97"}},{"content":"\n<p data-lines=\"97,98\">TRAILBLASER</p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Progression post 1st Line","children":[],"payload":{"lines":"99,100"}}],"payload":{"lines":"97,100"}}],"payload":{"lines":"90,100"}},{"content":"3","children":[{"content":"\n<p data-lines=\"101,102\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"103,104\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"103,106"}},{"content":"\n<p data-lines=\"106,107\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"106,107"}}],"payload":{"lines":"101,107"}}],"payload":{"lines":"100,107"}},{"content":"4","children":[{"content":"\n<p data-lines=\"108,109\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"110,111\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"110,113"}},{"content":"\n<p data-lines=\"113,114\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"113,114"}}],"payload":{"lines":"108,114"}}],"payload":{"lines":"107,114"}}],"payload":{"lines":"89,114"}},{"content":"HR POS","children":[{"content":"1","children":[{"content":"\n<p data-lines=\"116,117\">OPERA-02 [OPENING Fall 2026]</p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> DeNovo or recurrent in 1st Line using Palazestrant","children":[],"payload":{"lines":"118,119"}}],"payload":{"lines":"116,119"}},{"content":"\n<p data-lines=\"119,120\"><strong>EvoPAR-Breast01</strong></p>","children":[{"content":"\n<p data-lines=\"121,122\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> DenoVo metastatic opr 1ry resistant ER+ (&gt;1%)</p>","children":[],"payload":{"lines":"121,124"}},{"content":"\n<p data-lines=\"124,125\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> BRCA1/2 OR PALB2 (either germline or somatic)</p>","children":[],"payload":{"lines":"124,125"}}],"payload":{"lines":"119,125"}}],"payload":{"lines":"115,125"}},{"content":"2","children":[{"content":"\n<p data-lines=\"126,127\"><strong>ELAINE-III</strong></p>","children":[{"content":"\n<p data-lines=\"128,129\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Progression on 1st Line CDK4/6. ESR1 mutation</p>","children":[],"payload":{"lines":"128,131"}},{"content":"\n<p data-lines=\"131,132\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No priot Abema in adjuvant or metastatic setting</p>","children":[],"payload":{"lines":"131,132"}}],"payload":{"lines":"126,132"}},{"content":"\n<p data-lines=\"132,133\"><strong>OPERA-1 [CLOSED 06/2026]</strong></p>","children":[{"content":"\n<p data-lines=\"134,135\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Post 1st Line progression while on ET/CDK , adjuvant ET or within 2 years post ET. No prior Chemo in Stage 4.</p>","children":[],"payload":{"lines":"134,137"}},{"content":"\n<p data-lines=\"137,138\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Part A three arm for OP 120, OP 90 and SoC. Part B is OP vs SoC [Faslo or AI]</p>","children":[],"payload":{"lines":"137,138"}}],"payload":{"lines":"132,138"}},{"content":"\n<p data-lines=\"138,139\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"140,141\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"140,143"}},{"content":"\n<p data-lines=\"143,144\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"143,144"}}],"payload":{"lines":"138,144"}},{"content":"\n<p data-lines=\"144,145\">TRAILBLASER</p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Progression post 1st Line","children":[],"payload":{"lines":"146,147"}}],"payload":{"lines":"144,147"}},{"content":"\n<p data-lines=\"147,148\">EVOLVE-DBT</p>","children":[],"payload":{"lines":"147,149"}},{"content":"\n<p data-lines=\"149,150\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"151,152\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"151,154"}},{"content":"\n<p data-lines=\"154,155\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ HER2- must have progressed on or within 12 months of adjuvant ET, OR got minimum of 1L of ET (including prior CDK4/6)</p>","children":[],"payload":{"lines":"154,155"}}],"payload":{"lines":"149,155"}},{"content":"\n<p data-lines=\"155,156\"><strong>QuantifyHER</strong></p>","children":[{"content":"\n<p data-lines=\"157,158\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ IHC 1+ who will start Enhertu (Or within 30 days after starting)</p>","children":[],"payload":{"lines":"157,160"}},{"content":"\n<p data-lines=\"160,161\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible</p>","children":[],"payload":{"lines":"160,161"}}],"payload":{"lines":"155,161"}}],"payload":{"lines":"125,161"}},{"content":"3","children":[{"content":"\n<p data-lines=\"162,163\"><strong>OPERA-1 [CLOSED 06/2026]</strong></p>","children":[{"content":"\n<p data-lines=\"164,165\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Post 2 Lines Line of ET, lasting at least 6 months. No prior Chemo in Stage 4.</p>","children":[],"payload":{"lines":"164,167"}},{"content":"\n<p data-lines=\"167,168\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Part A three arm for OP 120, OP 90 and SoC. Part B is OP vs SoC [Faslo or AI]</p>","children":[],"payload":{"lines":"167,170"}},{"content":"\n<p data-lines=\"170,171\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If 2nd line was Faslo, 3rd line SoC can be AI</p>","children":[],"payload":{"lines":"170,171"}}],"payload":{"lines":"162,171"}},{"content":"\n<p data-lines=\"171,172\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"173,174\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"173,176"}},{"content":"\n<p data-lines=\"176,177\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"176,177"}}],"payload":{"lines":"171,177"}},{"content":"\n<p data-lines=\"177,178\">Verastem [OPENING 04/2026]</p>","children":[{"content":"\n<p data-lines=\"179,180\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Prior progression on CDK4/6i AND Fulvestrant</p>","children":[],"payload":{"lines":"179,182"}},{"content":"\n<p data-lines=\"182,183\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No more than 2 chemo lines</p>","children":[],"payload":{"lines":"182,183"}}],"payload":{"lines":"177,183"}},{"content":"\n<p data-lines=\"183,184\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"185,186\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"185,188"}},{"content":"\n<p data-lines=\"188,189\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Received 1st Line ET (including CDK4/6i), 2nd Line,</p>","children":[],"payload":{"lines":"188,189"}}],"payload":{"lines":"183,189"}},{"content":"\n<p data-lines=\"189,190\"><strong>Bicycle-201</strong></p>","children":[{"content":"\n<p data-lines=\"191,192\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Received Endocrine therapy (no limits) and a minimum of 1 chemo therapy in the metastatic setting, up to three chemo lines</p>","children":[],"payload":{"lines":"191,194"}},{"content":"\n<p data-lines=\"194,195\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NECTIN4 amplification required. Around 60% of Pts</p>","children":[],"payload":{"lines":"194,195"}}],"payload":{"lines":"189,195"}},{"content":"\n<p data-lines=\"195,196\"><strong>QuantifyHER</strong></p>","children":[{"content":"\n<p data-lines=\"197,198\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ IHC 1+ who will start Enhertu (Or within 30 days after starting)</p>","children":[],"payload":{"lines":"197,200"}},{"content":"\n<p data-lines=\"200,201\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible</p>","children":[],"payload":{"lines":"200,201"}}],"payload":{"lines":"195,201"}}],"payload":{"lines":"161,201"}},{"content":"4","children":[{"content":"\n<p data-lines=\"202,203\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"204,205\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"204,207"}},{"content":"\n<p data-lines=\"207,208\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"207,208"}}],"payload":{"lines":"202,208"}},{"content":"\n<p data-lines=\"208,209\">Verastem [OPENING 04/2026]</p>","children":[{"content":"\n<p data-lines=\"210,211\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Prior progression on CDK4/6i AND Fulvestrant</p>","children":[],"payload":{"lines":"210,213"}},{"content":"\n<p data-lines=\"213,214\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No more than 2 chemo lines</p>","children":[],"payload":{"lines":"213,214"}}],"payload":{"lines":"208,214"}},{"content":"\n<p data-lines=\"214,215\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"216,217\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"216,219"}},{"content":"\n<p data-lines=\"219,220\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Received 1st Line ET (including CDK4/6i), 2nd Line, and on 3rd Line ADC. Can join directly to ADC2 at 4th L from Dato or Enhertu</p>","children":[],"payload":{"lines":"219,220"}}],"payload":{"lines":"214,220"}},{"content":"\n<p data-lines=\"220,221\"><strong>Bicycle-201</strong></p>","children":[{"content":"\n<p data-lines=\"222,223\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Received Endocrine therapy (no limits) and a minimum of 1 chemo therapy in the metastatic setting, up to three chemo lines</p>","children":[],"payload":{"lines":"222,225"}},{"content":"\n<p data-lines=\"225,226\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NECTIN4 amplification required. Around 60% of Pts</p>","children":[],"payload":{"lines":"225,226"}}],"payload":{"lines":"220,226"}},{"content":"\n<p data-lines=\"226,227\"><strong>QuantifyHER</strong></p>","children":[{"content":"\n<p data-lines=\"228,229\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ IHC 1+ who will start Enhertu (Or within 30 days after starting)</p>","children":[],"payload":{"lines":"228,231"}},{"content":"\n<p data-lines=\"231,232\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible</p>","children":[],"payload":{"lines":"231,232"}}],"payload":{"lines":"226,232"}}],"payload":{"lines":"201,232"}},{"content":"5","children":[{"content":"\n<p data-lines=\"233,234\"><strong>Bicycle-201</strong></p>","children":[{"content":"\n<p data-lines=\"235,236\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Received Endocrine therapy (no limits) and a minimum of 1 chemo therapy in the metastatic setting, up to three chemo lines</p>","children":[],"payload":{"lines":"235,238"}},{"content":"\n<p data-lines=\"238,239\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NECTIN4 amplification required. Around 60% of Pts</p>","children":[],"payload":{"lines":"238,239"}}],"payload":{"lines":"233,239"}}],"payload":{"lines":"232,239"}}],"payload":{"lines":"114,239"}},{"content":"TNBC","children":[{"content":"1","children":[{"content":"\n<p data-lines=\"241,242\"><strong>TBCRC 061</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Receipt of Immunotherapy in the advanced setting","children":[],"payload":{"lines":"243,244"}}],"payload":{"lines":"241,244"}},{"content":"\n<p data-lines=\"244,245\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"246,247\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0+/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"246,249"}},{"content":"\n<p data-lines=\"249,250\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC Strict 0-1 prior lines.</p>","children":[],"payload":{"lines":"249,250"}}],"payload":{"lines":"244,250"}}],"payload":{"lines":"240,250"}},{"content":"2","children":[{"content":"\n<p data-lines=\"251,252\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"253,254\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"253,256"}},{"content":"\n<p data-lines=\"256,257\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"256,257"}}],"payload":{"lines":"251,257"}},{"content":"\n<p data-lines=\"257,258\">TRAILBLASER</p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Progression post 1st Line","children":[],"payload":{"lines":"259,260"}}],"payload":{"lines":"257,260"}},{"content":"\n<p data-lines=\"260,261\">EVOLVE-DBT</p>","children":[],"payload":{"lines":"260,262"}},{"content":"\n<p data-lines=\"262,263\"><strong>TBCRC 061</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Receipt of Immunotherapy in the advanced setting","children":[],"payload":{"lines":"264,265"}}],"payload":{"lines":"262,265"}},{"content":"\n<p data-lines=\"265,266\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"267,268\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0+/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"267,270"}},{"content":"\n<p data-lines=\"270,271\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC Strict 0-1 prior lines, but can join from Enhertu 2L to Dato</p>","children":[],"payload":{"lines":"270,271"}}],"payload":{"lines":"265,271"}},{"content":"\n<p data-lines=\"271,272\"><strong>Bicycle-201</strong></p>","children":[{"content":"\n<p data-lines=\"273,274\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Received minimum of 1 chemo therapy in the metastatic setting, up to three chemo lines</p>","children":[],"payload":{"lines":"273,276"}},{"content":"\n<p data-lines=\"276,277\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NECTIN4 amplification required. Around 60% of Pts</p>","children":[],"payload":{"lines":"276,277"}}],"payload":{"lines":"271,277"}},{"content":"\n<p data-lines=\"277,278\"><strong>QuantifyHER</strong></p>","children":[{"content":"\n<p data-lines=\"279,280\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER- IHC 1+ who will start Enhertu (Or within 30 days after starting)</p>","children":[],"payload":{"lines":"279,282"}},{"content":"\n<p data-lines=\"282,283\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible\"</p>","children":[],"payload":{"lines":"282,283"}}],"payload":{"lines":"277,283"}}],"payload":{"lines":"250,283"}},{"content":"3","children":[{"content":"\n<p data-lines=\"284,285\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"286,287\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"286,289"}},{"content":"\n<p data-lines=\"289,290\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"289,290"}}],"payload":{"lines":"284,290"}},{"content":"\n<p data-lines=\"290,291\"><strong>TBCRC 061</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Receipt of Immunotherapy in the advanced setting","children":[],"payload":{"lines":"292,293"}}],"payload":{"lines":"290,293"}},{"content":"\n<p data-lines=\"293,294\"><strong>Bicycle-201</strong></p>","children":[{"content":"\n<p data-lines=\"295,296\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Received minimum of 1 chemo therapy in the metastatic setting, up to three chemo lines</p>","children":[],"payload":{"lines":"295,298"}},{"content":"\n<p data-lines=\"298,299\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NECTIN4 amplification required. Around 60% of Pts</p>","children":[],"payload":{"lines":"298,299"}}],"payload":{"lines":"293,299"}},{"content":"\n<p data-lines=\"299,300\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"301,302\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0+/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"301,304"}},{"content":"\n<p data-lines=\"304,305\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC Strict 0-1 prior lines, but can join from Enhertu 2L to Dato</p>","children":[],"payload":{"lines":"304,305"}}],"payload":{"lines":"299,305"}},{"content":"\n<p data-lines=\"305,306\"><strong>QuantifyHER</strong></p>","children":[{"content":"\n<p data-lines=\"307,308\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER- IHC 1+ who will start Enhertu (Or within 30 days after starting)</p>","children":[],"payload":{"lines":"307,310"}},{"content":"\n<p data-lines=\"310,311\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible\"</p>","children":[],"payload":{"lines":"310,311"}}],"payload":{"lines":"305,311"}}],"payload":{"lines":"283,311"}},{"content":"4","children":[{"content":"\n<p data-lines=\"312,313\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"314,315\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"314,317"}},{"content":"\n<p data-lines=\"317,318\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"317,318"}}],"payload":{"lines":"312,318"}},{"content":"\n<p data-lines=\"318,319\"><strong>Bicycle-201</strong></p>","children":[{"content":"\n<p data-lines=\"320,321\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Received minimum of 1 chemo therapy in the metastatic setting, up to three chemo lines</p>","children":[],"payload":{"lines":"320,323"}},{"content":"\n<p data-lines=\"323,324\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NECTIN4 amplification required. Around 60% of Pts</p>","children":[],"payload":{"lines":"323,324"}}],"payload":{"lines":"318,324"}}],"payload":{"lines":"311,324"}}],"payload":{"lines":"239,324"}}],"payload":{"lines":"88,324"}},{"content":"Neoadjuvant","children":[{"content":"HER2","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"327,328\"><strong>RESPONSE</strong></p>","children":[{"content":"\n<p data-lines=\"329,330\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers</p>","children":[],"payload":{"lines":"329,332"}},{"content":"\n<p data-lines=\"332,333\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Will receive weekly Taxol HP  with ddAC</p>","children":[],"payload":{"lines":"332,333"}}],"payload":{"lines":"327,333"}},{"content":"\n<p data-lines=\"333,334\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"335,336\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"335,338"}},{"content":"\n<p data-lines=\"338,339\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"338,339"}}],"payload":{"lines":"333,339"}},{"content":"\n<p data-lines=\"339,340\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"341,342"}}],"payload":{"lines":"339,342"}}],"payload":{"lines":"326,342"}}],"payload":{"lines":"325,342"}},{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"344,345\"><strong>RESPONSE</strong></p>","children":[{"content":"\n<p data-lines=\"346,347\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers</p>","children":[],"payload":{"lines":"346,349"}},{"content":"\n<p data-lines=\"349,350\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> High Risk ER+ (Grade III, Age &lt;50, ER &lt; 6/8 OR Ki67 &gt;29%). Will receive weekly Taxol with ddAC</p>","children":[],"payload":{"lines":"349,350"}}],"payload":{"lines":"344,350"}},{"content":"\n<p data-lines=\"350,351\"><strong>EVANGELINE [CLOSING 08/2026]</strong></p>","children":[{"content":"\n<p data-lines=\"352,353\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Clinical T2 or T3 and N0 or N1 with Grade I and II</p>","children":[],"payload":{"lines":"352,355"}},{"content":"\n<p data-lines=\"355,356\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ 67% or more, Allred 6-8</p>","children":[],"payload":{"lines":"355,356"}}],"payload":{"lines":"350,356"}},{"content":"\n<p data-lines=\"356,357\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"358,359\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"358,361"}},{"content":"\n<p data-lines=\"361,362\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"361,362"}}],"payload":{"lines":"356,362"}},{"content":"\n<p data-lines=\"362,363\">NCBRE [OPENING Fall 2026]</p>","children":[{"content":"\n<p data-lines=\"364,365\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ILC ER+ PR+ HER2- with ERBB2 mutation.</p>","children":[],"payload":{"lines":"364,367"}},{"content":"\n<p data-lines=\"367,368\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1c (Min size 15mm) N0/N1/N2</p>","children":[],"payload":{"lines":"367,368"}}],"payload":{"lines":"362,368"}},{"content":"\n<p data-lines=\"368,369\"><strong>S2206</strong></p>","children":[{"content":"\n<p data-lines=\"370,371\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Stage II and III, including IBC. ER+ or PR+ per CAP (&gt;1%)</p>","children":[],"payload":{"lines":"370,373"}},{"content":"\n<p data-lines=\"373,374\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> High 2 on MP</p>","children":[],"payload":{"lines":"373,374"}}],"payload":{"lines":"368,374"}},{"content":"\n<p data-lines=\"374,375\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"376,377"}}],"payload":{"lines":"374,377"}}],"payload":{"lines":"343,377"}}],"payload":{"lines":"342,377"}},{"content":"TNBC","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"379,380\"><strong>RESPONSE</strong></p>","children":[{"content":"\n<p data-lines=\"381,382\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers</p>","children":[],"payload":{"lines":"381,384"}},{"content":"\n<p data-lines=\"384,385\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Will receive weekly Taxol with ddAC (Pembro added if indicated, Carbo added if T3)</p>","children":[],"payload":{"lines":"384,385"}}],"payload":{"lines":"379,385"}},{"content":"\n<p data-lines=\"385,386\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"387,388\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"387,390"}},{"content":"\n<p data-lines=\"390,391\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"390,391"}}],"payload":{"lines":"385,391"}},{"content":"\n<p data-lines=\"391,392\"><strong>S2212</strong></p>","children":[{"content":"\n<p data-lines=\"393,394\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC (ER/PR &lt;5%) with T2-T4 N0 OR T1-T3 N1-N2. Randomized to either KN522 versus Taxotere Carbo  Pembro x 6 Cycles</p>","children":[],"payload":{"lines":"393,396"}},{"content":"\n<p data-lines=\"396,397\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No Stage IIIC, IIIB T4 N+ OR IBC</p>","children":[],"payload":{"lines":"396,397"}}],"payload":{"lines":"391,397"}},{"content":"\n<p data-lines=\"397,398\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"399,400"}}],"payload":{"lines":"397,400"}},{"content":"\n<p data-lines=\"400,401\"><strong>TNBC ctDNA Tissue Banking</strong></p>","children":[{"content":"\n<p data-lines=\"402,403\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC Stage II/III receiving NACT (+/- ICB)</p>","children":[],"payload":{"lines":"402,405"}},{"content":"\n<p data-lines=\"405,406\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ctDNA collected after Taxol and after AC, both before definitive surgery</p>","children":[],"payload":{"lines":"405,406"}}],"payload":{"lines":"400,406"}}],"payload":{"lines":"378,406"}}],"payload":{"lines":"377,406"}}],"payload":{"lines":"324,406"}}],"payload":{"lines":"23,406"}},{"content":"RAD ONC","children":[{"content":"Postsurgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"410,411\">PREDICT II</p>","children":[{"content":"\n<p data-lines=\"412,413\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dx of DCIS w/ tumor size &lt;6cm</p>","children":[],"payload":{"lines":"412,415"}},{"content":"\n<p data-lines=\"415,416\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Eligible for BCS, radiation and/or systemic treatment</p>","children":[],"payload":{"lines":"415,416"}}],"payload":{"lines":"410,416"}}],"payload":{"lines":"409,416"}}],"payload":{"lines":"408,416"}}],"payload":{"lines":"407,416"}}],"payload":{"lines":"406,416"}},{"content":"SURG ONC","children":[{"content":"Peri-Surgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"420,421\"><strong>Breast ATLAS</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Undergoing PPX Mastectomy","children":[],"payload":{"lines":"422,423"}}],"payload":{"lines":"420,423"}},{"content":"\n<p data-lines=\"423,424\"><strong>PRECISION</strong></p>","children":[{"content":"\n<p data-lines=\"425,426\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dx of DCIS and/or IDC undergoing BCS or mastectomy</p>","children":[],"payload":{"lines":"425,428"}},{"content":"\n<p data-lines=\"428,429\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No hx of prior therapy treatment</p>","children":[],"payload":{"lines":"428,429"}}],"payload":{"lines":"423,429"}},{"content":"\n<p data-lines=\"429,430\"><strong>SentiNot 2.0</strong></p>","children":[{"content":"\n<p data-lines=\"431,432\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Pre-operative diagnosis of DCIS or other suspicious lesion not confirmed to be invasive breast cancer</p>","children":[],"payload":{"lines":"431,434"}},{"content":"\n<p data-lines=\"434,435\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Willing to forgo initial SLNB and have SLNB as a later second procedure if DCIS is upgraded to invasive cancer</p>","children":[],"payload":{"lines":"434,435"}}],"payload":{"lines":"429,435"}},{"content":"\n<p data-lines=\"435,436\"><strong>Magellan</strong></p>","children":[{"content":"\n<p data-lines=\"437,438\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Non-metastatic patients with node positive breast cancer (cT0-4, N1)</p>","children":[],"payload":{"lines":"437,440"}},{"content":"\n<p data-lines=\"440,441\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Magseed placement prior to NAC</p>","children":[],"payload":{"lines":"440,441"}}],"payload":{"lines":"435,441"}}],"payload":{"lines":"419,441"}}],"payload":{"lines":"418,441"}}],"payload":{"lines":"417,441"}},{"content":"Postsurgical","children":[{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"444,445\"><strong>LoTAM</strong></p>","children":[{"content":"\n<p data-lines=\"446,447\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Stage 1 and 2A (T &lt; 30mm, N0) ER+ (&gt;10%) HER2- Breast Cancer</p>","children":[],"payload":{"lines":"446,449"}},{"content":"\n<p data-lines=\"449,450\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> LOW Genomic risk (MP LOW, RS &lt;26 OR ProSigna &lt;40)</p>","children":[],"payload":{"lines":"449,450"}}],"payload":{"lines":"444,450"}}],"payload":{"lines":"443,450"}}],"payload":{"lines":"442,450"}}],"payload":{"lines":"441,450"}},{"content":"Presurgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"453,454\"><strong>BCM TISSUE COLLECTION</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Suspicious lesion receiving an U/S guided biopsy with birads 4b-5","children":[],"payload":{"lines":"455,456"}}],"payload":{"lines":"453,456"}},{"content":"\n<p data-lines=\"456,457\"><strong>ANGEL</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Any suspicious lesion receiving a biopsy","children":[],"payload":{"lines":"458,459"}}],"payload":{"lines":"456,459"}}],"payload":{"lines":"452,459"}}],"payload":{"lines":"451,459"}}],"payload":{"lines":"450,459"}}],"payload":{"lines":"416,459"}}],"payload":{"lines":"0,459"}};
const jsonOptions = {"initialExpandLevel":4,"maxWidth":250,"duration":400,"spacingVertical":8,"spacingHorizontal":100,"autoFit":true};

// Build search index from tree
const searchIndex = [];

function traverseTree(node, path = []) {
  const content = node.content || node.v || '';
  const currentPath = [...path, content];

  // Check if this is a trial node (bold or has status brackets, but not [x] criteria)
  const isTrialNode = (content.includes('<strong>') ||
                       content.includes('[OPENING') ||
                       content.includes('[CLOSING') ||
                       content.includes('[CLOSED')) &&
                      !content.includes('[x]');

  if (isTrialNode) {
    // Clean up name for search
    const cleanName = content
      .replace(/<[^>]*>/g, '')  // Remove HTML tags
      .replace(/\[.*?\]/g, '')  // Remove brackets
      .trim();

    searchIndex.push({
      name: cleanName,
      path: path.filter(p => !p.includes('[x]')).join(' > '),
      node: node
    });
  }

  if (node.children) {
    node.children.forEach(child => traverseTree(child, currentPath));
  }
}

traverseTree(root);

// Search functionality
const searchInput = document.getElementById('searchInput');
const searchResults = document.getElementById('searchResults');

searchInput.addEventListener('input', (e) => {
  const query = e.target.value.toLowerCase().trim();

  if (query.length < 2) {
    searchResults.classList.remove('active');
    document.querySelectorAll('.markmap-node').forEach(n => n.classList.remove('dimmed'));
    return;
  }

  const matches = searchIndex.filter(item =>
    item.name.toLowerCase().includes(query) ||
    item.path.toLowerCase().includes(query)
  ).slice(0, 10);

  if (matches.length > 0) {
    searchResults.innerHTML = matches.map(m => `
      <div class="search-result-item" data-name="${m.name}">
        <div class="trial-name">${m.name}</div>
        <div class="trial-path">${m.path}</div>
      </div>
    `).join('');
    searchResults.classList.add('active');

    // Dim non-matching nodes
    const matchNames = new Set(matches.map(m => m.name.toLowerCase()));
    document.querySelectorAll('.markmap-node').forEach(node => {
      const text = node.textContent.toLowerCase();
      const hasMatch = Array.from(matchNames).some(name => text.includes(name));
      node.classList.toggle('dimmed', !hasMatch);
    });
  } else {
    searchResults.innerHTML = '<div class="search-result-item"><div class="trial-name">No results found</div></div>';
    searchResults.classList.add('active');
  }
});

searchInput.addEventListener('blur', () => {
  setTimeout(() => {
    searchResults.classList.remove('active');
  }, 200);
});

searchResults.addEventListener('click', (e) => {
  const item = e.target.closest('.search-result-item');
  if (item) {
    searchInput.value = item.dataset.name;
    searchResults.classList.remove('active');
  }
});

document.addEventListener('keydown', (e) => {
  if (e.key === 'Escape') {
    searchInput.value = '';
    searchResults.classList.remove('active');
    document.querySelectorAll('.markmap-node').forEach(n => n.classList.remove('dimmed'));
  }
});

// WebFont loading
window.WebFontConfig = {
  custom: {
    families: [
      "KaTeX_AMS","KaTeX_Caligraphic:n4,n7","KaTeX_Fraktur:n4,n7",
      "KaTeX_Main:n4,n7,i4,i7","KaTeX_Math:i4,i7","KaTeX_Script",
      "KaTeX_SansSerif:n4,n7,i4","KaTeX_Size1","KaTeX_Size2",
      "KaTeX_Size3","KaTeX_Size4","KaTeX_Typewriter"
    ],
    active: function() {
      window.markmap.refreshHook.call();
    }
  }
};

// Create dynamic stylesheet for theme-based colors
// This injects CSS that uses !important to override ALL markmap styles
function injectThemeStyles() {
  // Remove old dynamic styles
  const oldStyle = document.getElementById('dynamic-theme-styles');
  if (oldStyle) oldStyle.remove();

  const isDark = document.documentElement.getAttribute('data-theme') === 'dark';
  const textColor = isDark ? '#f1f5f9' : '#1e293b';

  const css = `
    /* Force text color on ALL possible markmap elements */
    #mindmap text,
    #mindmap tspan,
    #mindmap foreignObject,
    #mindmap foreignObject *,
    #mindmap .markmap-node text,
    #mindmap .markmap-node tspan,
    #mindmap .markmap-foreign-object,
    #mindmap .markmap-foreign-object *,
    #mindmap [class*="markmap"] text,
    #mindmap [class*="markmap"] tspan,
    #mindmap g text,
    #mindmap g tspan,
    .markmap text,
    .markmap tspan,
    svg text,
    svg tspan {
      fill: ${textColor} !important;
      color: ${textColor} !important;
      font-family: 'Nunito', Tahoma, Geneva, Verdana, sans-serif !important;
    }

    /* Status colors - these should still work */
    #mindmap text:has-text("[CLOSED"),
    #mindmap foreignObject:has-text("[CLOSED") * {
      fill: #ef4444 !important;
      color: #ef4444 !important;
      opacity: 0.6 !important;
    }
  `;

  const style = document.createElement('style');
  style.id = 'dynamic-theme-styles';
  style.textContent = css;
  document.head.appendChild(style);

  // Directly modify ALL elements in the SVG
  setTimeout(() => {
    const svg = document.getElementById('mindmap');
    if (!svg) return;

    // Get ALL text-containing elements
    const allElements = svg.querySelectorAll('*');
    console.log('Found ' + allElements.length + ' elements in mindmap');

    allElements.forEach(el => {
      const tagName = el.tagName.toLowerCase();

      // For text and tspan elements (SVG text)
      if (tagName === 'text' || tagName === 'tspan') {
        el.setAttribute('fill', textColor);
        el.setAttribute('style', 'fill: ' + textColor + ' !important; font-family: Nunito, Tahoma, sans-serif !important;');
      }

      // For foreignObject content (HTML inside SVG)
      if (tagName === 'div' || tagName === 'span' || tagName === 'strong' || tagName === 'p') {
        el.setAttribute('style', 'color: ' + textColor + ' !important; font-family: Nunito, Tahoma, sans-serif !important;');
      }

      // For foreignObject itself
      if (tagName === 'foreignobject') {
        el.querySelectorAll('*').forEach(child => {
          child.setAttribute('style', 'color: ' + textColor + ' !important; font-family: Nunito, Tahoma, sans-serif !important;');
        });
      }
    });
  }, 200);
}

// Run repeatedly to catch Markmap re-renders
let styleInterval;
function startStyleUpdater() {
  // Clear any existing interval
  if (styleInterval) clearInterval(styleInterval);

  // Inject styles immediately
  injectThemeStyles();

  // Re-apply every 500ms for 5 seconds to catch async renders
  let count = 0;
  styleInterval = setInterval(() => {
    injectThemeStyles();
    count++;
    if (count >= 10) clearInterval(styleInterval);
  }, 500);
}

// Initialize markmap
(() => {
  setTimeout(() => {
    const { markmap: Markmap, mm: markmapInstance } = window;
    const toolbar = new Markmap.Toolbar();
    toolbar.attach(markmapInstance);
    const toolbarElement = toolbar.render();
    toolbarElement.style.position = 'absolute';
    toolbarElement.style.bottom = '24px';
    toolbarElement.style.right = '24px';
    document.body.append(toolbarElement);

    // Apply styles (font, colors)
    startStyleUpdater();

    // Re-apply on any markmap updates
    const observer = new MutationObserver(() => {
      applyNodeStyles();
    });
    observer.observe(document.getElementById('mindmap'), {
      childList: true,
      subtree: true
    });
  });

  ((getMarkmap, getOptions, root, jsonOptions) => {
    const markmap = getMarkmap();
    window.mm = markmap.Markmap.create(
      "svg#mindmap",
      (getOptions || markmap.deriveOptions)(jsonOptions),
      root
    );
  })(() => window.markmap, null, root, jsonOptions);
})();
</script>
<script src="https://cdn.jsdelivr.net/npm/webfontloader@1.6.28/webfontloader.js" defer></script>
</body>
</html>
